Introduction: As current evidence regarding the protective role of coenzyme Q10 on atrial fibrillation is inconclusive, we undertook a meta-analysis to investigate the impact of coenzyme Q10 on the prevention of postoperative atrial fibrillation following cardiac surgery. Methods: A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Library databases was conducted to identify relevant randomized controlled trials. The search encompassed the period from the inception of the databases to April 1st, 2024, without language restrictions. Meta-analysis was carried out with Review Manager 5.3. The risk ratio (RR) was employed to assess the effect. Results: Five randomized controlled trials with 216 patients were finally included. It was shown that perioperative use of coenzyme Q10 significantly reduced the incidence of postoperative atrial fibrillation compared with the control group (RR: 0.55; 95% CI: 0.33-0.90; P=0.02; I 2=0%). Conclusion: Coenzyme Q10 might be a prophylactic treatment for postoperative atrial fibrillation following cardiac surgery.

Background: The anterior and lateral position of the anterolateral papillary muscle (ALPM) has found to be reached with better catheter stability and less mechanical bumping via the transseptal (TS) compared to the retrograde aortic (RA) approach. Aim: To compare the TS and RA approaches on mapping and ablation of ventricular arrhythmias (VAs) arising from ALPMs. Methods: Thirty-two patients with ALPM-VAs undergoing mapping and ablation via the TS approach were included and compared with 31 patients via the RA approach within the same period. Acute success was compared, as well as other outcomes including misinterpreted mapping results due to bumping, radiofrequency (RF) attempts, procedural time and success rate at 12 months’ follow-up. Results: Acute success was achieved in more cases in the TS group (96.4% vs 72.0%, P=0.020). During activation mapping, bump-provoked premature ventricular complexes (PVCs) misinterpreted as clinical PVCs were more common in the RA group (30.0% vs 58.3%, P=0.036), leading to more RF attempts (3.5±2.7 vs 7.2±6.8, P=0.006). Suppression of VAs were finally achieved in the unsuccessful cases by changing to the alternative approach, but the procedural time was significantly less in the TS group (90.0±33.0 vs 113.7±41.1min, P=0.027) with less need to change the approach, although follow-up success rates were similar (75.0% vs 71.0%, P=0.718). Conclusion: A TS rather than RA approach as the initial approach appears to facilitate mapping and ablation of ALPM-VAs, specifically by decreasing the possibility of misleading mapping results caused by bump-provoked PVC, and increase the acute success rate thereby.

Introduction: The safety and effectiveness of catheter ablation in patients with atrial fibrillation (AF) who underwent mechanical mitral valve replacement (MVR) have been reported. However, the impacts of different types of mitral valves on the safety and effectiveness of catheter ablation in patients with AF who underwent MVR have not been elucidated. Methods and results: From 2015 to 2021, 17,496 patients underwent catheter ablation of AF for the first time in Beijing Anzhen Hospital were screened. The inclusion criteria were (1) aged 18 years or older; (2) diagnosed with AF; (3) history of mitral valve replacement. The exclusion criteria were a history of catheter ablation, surgical maze procedure, left atrial appendage closure or resection. A total of 68 patients were enrolled in the study. The patients were divided into two groups: the bioprosthetic MVR group (n=12) and the mechanical MVR group(n=58). The size of the left atrial was larger (49.5mm vs. 46.0mm, p<0.05), the thickness of the left interventricular septum was larger (11.0mm vs. 10.0mm, p<0.05), and the mitral ring area was smaller (2.3mm2 vs. 2.6mm2, p<0.05) for the bioprosthetic MVR group than the mechanical MVR group. During 23.4 (6.1, 36.5) months of follow-up, the incidence of the endpoint events was not significantly different between the two groups (33.3% vs. 30.4%, log-rank p=0.48). There were 2 cases (3.4%) of pseudoaneurysm and 1 case of acute cerebral infarction in the mechanical MVR group. No complication was observed in the bioprosthetic MVR group. No significant clinical bleeding events were observed in the bioprosthetic group while eight patients in the mechanical MVR groups had bleeding events (p=0.368) during the follow-up. Conclusion: The safety and effectiveness of catheter ablation of AF were comparable between the patients with mechanical MVR and bioprosthetic MVR.

Background: CLBBB and AF are not uncommon coexisted. The impact of CLBBB on long-term prognosis of catheter ablation of AF has not been well determined. Objectives: This study aims to explore the long-term outcomes of patients with atrial fibrillation (AF) and complete left bundle branch block (CLBBB) after catheter ablation. Methods: Forty-two patients with CLBBB of the 11,752 patients who underwent catheter ablation of AF from 2011 to 2020 were enrolled as CLBBB group. After propensity score matching in a 1:4 ratio, 168 AF patients without CLBBB were enrolled as Non-CLBBB group. The primary endpoint was a composite of stroke, all-cause mortality, and cardiovascular hospitalization. The secondary endpoint was AF recurrence after single ablation. Results: The incidence of the primary endpoint in the CLBBB group was significantly higher than in the Non-CLBBB group (21.4% vs. 6.5%, HR 3.98, 95%CI 1.64-9.64, P = 0.002). The recurrence rates in the CLBBB group and the Non-CLBBB group were 54.8% and 31.5% (HR 1.71, 95%CI 1.04-2.79, P = 0.034), respectively. Multivariate analysis showed that CLBBB was an independent risk factor for both primary endpoint (HR 2.92, 95%CI 1.17-3.34, P = 0.022) and secondary endpoint (HR 2.19, 95%CI 1.09-4.40, P = 0.031) in patients with AF after catheter ablation. Conclusions: CLBBB significantly increased the risk of a composite endpoint of stroke, all-cause mortality, and cardiovascular hospitalization after catheter ablation in patients with AF. CLBBB also independently predicted recurrence in these patients.

Abstract Introduction: Linear ablation in addition to pulmonary vein antrum isolation (PVAI) has failed to improve the success rate for persistent atrial fibrillation (PeAF), due to incomplete block of ablation lines, especially in the mitral isthmus (MI). Methods and results: The study enrolled 191 patients (66 in group 1 and 125 in group 2). In group 1, EI-VOM was firstly performed, followed by radiofrequency (RF) applications targeting bilateral PVAI and bidirectional block in the roofline, cavotricuspid isthmus, and MI. In group 2, PVAI and the three linear ablations were completed using only RF energy. MI block was achieved in 63(95.5%) and 101(80.8%) patients in group 1 and 2, respectively (p=0.006). Patients in group 1 had shorter ablation time for left pulmonary vein antrum (8.15 min vs 12.59 min, p<0.001) and MI (7.0 min vs 11.8 min, p<0.001) and required less cardioversion (50(78.5%) vs 113(90.4%), p=0.007). During the 12-month follow-up, 58 (87.9%) patients were free from AF/AT in group 1 compared with 81 (64.8%) in group 2 (p<0.001). In multivariate cox regression, the ‘upgraded 2C3L’ procedure is associated with a lower recurrence rate (HR 0.27, 95%CI 0.12-0.59). Conclusion: Compared with the conventional ‘2C3L’ approach, the ‘upgraded 2C3L’ approach has higher effectiveness for ablation of PeAF.

Background: Atrial fibrillation (AF) is common in abdominal solid organ transplant recipients and a cause of morbidity and mortality in this population. However, the outcomes of catheter ablation (CA) in transplant recipients with AF remain unclear. This study aimed to elucidate the outcomes of CA in renal and hepatic transplant recipients. Methods and Results: Between 2015 and 2019, 14 transplant recipients (9 with kidney transplantation and 5 with liver transplantation) were enrolled from among 10,741 AF patients and underwent CA at Anzhen Hospital. Another 56 patients matched by age, sex and AF type were selected as the control group (4 controls for each transplant recipient). During a mean follow-up of 30.0±13.3 months after the initial procedure, 10 (71.4%) of the transplant patients, compared to 41 (73.2%) of the control patients, remained free from AF recurrence(P=1.000). A repeated procedure was performed in 1 transplant patient and in 6 control subjects. Consequently, 11 (78.6%) of the transplant patients, compared to 46 (82.1%) of controls, were in sinus rhythm after the repeated ablation (P=0.715). Notably, Kaplan–Meier analysis did not demonstrate any significant differences in the atrial arrhythmia-free rate after the initial and repeated procedure between the two groups. Vascular complications were identified in 1 transplant patient and 2 control subjects, while no life-threatening complications were observed in either group. There was no transient allograft dysfunction in transplant recipients after CA. Conclusion: CA is safe and effective in abdominal solid transplant recipients, and may be an optimal therapeutic strategy for this group.